Patents by Inventor Giangiacomo Torri

Giangiacomo Torri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10875936
    Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: December 29, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10822430
    Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 3, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200216577
    Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200190224
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200172636
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20170233501
    Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Application
    Filed: October 22, 2014
    Publication date: August 17, 2017
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20160297896
    Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Application
    Filed: October 22, 2014
    Publication date: October 13, 2016
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20160237178
    Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glucosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glucosaminoglycan derivatives are obtained from natural or synthetic glucosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glucosaminoglycan by oxidation of said glucosaminoglycan.
    Type: Application
    Filed: October 23, 2014
    Publication date: August 18, 2016
    Applicant: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE "G.RONZONI" S.R.
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20150100249
    Abstract: A method of analysis of a heterogeneous product, for example heparin or heparin derivatives, to define whether said heterogeneous product is consistent with a library of verified heterogeneous samples (Library 1) by analysing the variation, natural or alien. The acceptable variation of the heterogeneous product is determined by comparing Library 1 with a second set of verified spectra (Library 2), by use of comparative two-dimensional correlation spectroscopic filtering (comparative 2D-COS-f). The method comprises obtaining a one-dimensional complex spectrum, for example 1H-NMR spectra, of a heterogeneous product and testing if it has features that are greater than features found testing a spectrum from Library 2 against Library 1. In a second embodiment comparative 2D-COS-f with iterative random sampling (2D-COS-firs) is applied, which provides a more accurate and stable extraction of aliens/unnatural features.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 9, 2015
    Applicants: Istituto Di Ricerche Chimiche E Biochimiche "G. Ronzoni", Anglo-Italian Chemometrics LTD.
    Inventors: Giangiacomo Torri, Marco Guerrini, Timothy Robert Rudd
  • Patent number: 8853387
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: October 7, 2014
    Assignee: Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Publication number: 20120232263
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Application
    Filed: July 9, 2009
    Publication date: September 13, 2012
    Applicant: Istituto Scientifico Di Chimica E Biochimica "G" R
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Patent number: 8222231
    Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: July 17, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Patent number: 8067555
    Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: November 29, 2011
    Assignee: Sigma-Tau Research Switzerland S.A.
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Patent number: 8018231
    Abstract: The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: September 13, 2011
    Assignees: Massachussetts Institute of Technology, Istituto di Ricerche Chimiche e Biochimiche G Ronzoni
    Inventors: Ram Sasisekharan, Ganesh Venkataraman, Rahul Raman, Benito Casu, Giangiacomo Torri, Marco Guerrini
  • Patent number: 7939512
    Abstract: The present invention is directed to a multistep process for the physical depolymerization of heparin wherein heparin is subjected to at least two ?-ray irradiations and wherein between two irradiation steps the depolymerised heparin is subjected to a separation step and only a fraction of the depolymerised heparin obtained from the first irradiation is subjected to the second irradiation step. It is also directed to heparin-derived oligosaccharide fractions obtainable by the process of the invention.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: May 10, 2011
    Assignee: Laboratori Derivati Organici SpA
    Inventors: Luigi De Ambrosi, Sergio Gonella, Donata Bensi, Giangiacomo Torri, Antonella Bisio, Elena Vismara
  • Publication number: 20100298263
    Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.
    Type: Application
    Filed: August 5, 2010
    Publication date: November 25, 2010
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Patent number: 7790700
    Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: September 7, 2010
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Publication number: 20100216176
    Abstract: The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.
    Type: Application
    Filed: May 5, 2010
    Publication date: August 26, 2010
    Applicants: Massachusetts Institute of Technology, Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni
    Inventors: RAM SASISEKHARAN, Ganesh Venkataraman, Rahul Raman, Benito Casu, Giangiacomo Torri, Marco Guerrini
  • Patent number: 7781416
    Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: August 24, 2010
    Assignee: Sigma-Tau Research Switzerland S.A.
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Patent number: 7754878
    Abstract: Polysaccharides are functionalized using a source of free radicals which forms stable radicals on the polysaccharides structure and wherein the formed radicals reacts with a functionalized unsaturated compound. The method comprises two steps: a first step, wherein the free radical on the polysaccharides chain is formed, and a second step, wherein said radical reacts with the unsaturated compound in the absence of the radical source.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: July 13, 2010
    Assignees: Next Technology Tecnotessile Societa Nazionale Di Ricerca R.L., Instuto Scientifico Di Chimica E Biochimica “G. Rozoni”
    Inventors: Giangiacomo Torri, Angelo Alberti, Sabrina Bertini, Gianluca Ciardelli, Giuseppe Gastaldi, Solitario Nesti, Elena Vismara